Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bradley, Nycomed Group A/S deal

Nycomed will acquire BDY for $20 per share, or $346 million in cash. The price

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE